Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
N
Shared by NobleBlocks on Dec 1, 2022 • 12:00 AM UTC
Authors:
C.E. Geyer
,
J.E. Garber
,
R.D. Gelber
Research Assistant
AI chat, annotations, notes & similar papers
Finding related papers...
Discussions
(0)
No comments yet
Be the first to share your thoughts!
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer | NobleBlocks
